Citations

Clear

634 citation(s) found for "Hall, A".

Identification of New Genetic Susceptibility Loci for Breast Cancer Through Consideration of Gene‐Environment Interactions
Schoeps, Anja , Dunning, Alison M. , Bojesen, Stig E. , Swerdlow, Anthony J. , Andrulis, Irene L. , Brenner, Hermann , Orr, Nicholas, Jones, Michael E. , Ashworth, Alan , Li, Jingmei , Cramp, Helen, Connley, Dan, Czene, Kamila , Darabi, Hatef, Lissowska, Jolanta , Figueroa, Jonine D. , Knight, Julia A. , Glendon, Gord, Mulligan, Anna Marie , Dumont, Martine , Severi, Gianluca , Baglietto, Laura , Vachon, Celine M., Purrington, Kristen S. , Moisse, Matthieu , Neven, Patrick , Wildiers, Hans , Spurdle, Amanda B. , Kosma, Veli‐Matti , Kataja, Vesa , Hartikainen, Jaana M. , Hamann, Ute, Ko, Yon‐Dschun, Dieffenbach, Aida Karina, Stegmaier, Christa, Malats, Núria , Flyger, Henrik, Nordestgaard, Børge G. , Truong, Thérèse , Cordina‐Duverger, Emilie, Ménégaux, F. , Fletcher, Olivia , Johnson, Nichola , Häberle, Lothar , Beckmann, Matthias W. , Ekici, Arif B. , Braaf, Linde M., Atsma, Femke , Broek, Alexandra J. van den, Makalic, Enes , Southey, Melissa C. , Cox, Angela , Simard, Jacques , Giles, Graham G. , Lambrechts, Diether , Mannermaa, Arto, Brauch, Hiltrud , Guénel, Pascal , Peto, Julian , Fasching, Peter A. , Hopper, John L. , Flesch‐Janys, Dieter, Couch, Fergus, Chenevix‐Trench, Georgia , García‐Closas, Montserrat , Schmidt, Marjanka K. , Easton, Douglas F. , Chang‐Claude, Jenny, Durocher, Francine , Orr, Nick , Thorne, Heather , Lambrechts, Diether , Rudolph, Anja , Seibold, Petra , Milne, Roger L. , Behrens, Sabine , Orr, Nicholas, Chanock, Stephen Jacob , Olson, Janet E. , Arndt, Volker , Pérez, José Ignacio Arias , Benı́tez, Javier , dos‐Santos‐Silva, Isabel , Schmidt, Daniel F. , Mannermaa, Arto, Pharoah, Paul D.P. , Hall, Per N , Lambrechts, Diether , Giles, Graham G , Spurdle, Amanda B , Swerdlow, Anthony J , Lissowska, Jolanta , Southey, Melissa C , Malats, Nuria , Dunning, Alison M , Jones, Michael E , Lambrechts, Diether , Brenner, Hermann , Cox, Angela , Guénel, Pascal , Li, Jingmei , García-Closas, Montserrat , Schmidt, Marjanka K , Severi, Gianluca , Makalic, Enes , Ekici, Arif B , Moisse, Matthieu , Hartikainen, Jaana M , Simard, Jacques , Chenevix-Trench, Georgia , Figueroa, Jonine D , Czene, Kamila , Baglietto, Laura , Fletcher, Olivia , Bojesen, Stig E , Purrington, Kristen S , Truong, Therese , Wildiers, Hans , Brauch, Hiltrud , Orr, Nick

Mayo Clinic

Genetic Epidemiology | November 19, 2013 | Volume: 38 | Issue: 1 | Pages: 84-93

10.1002/gepi.21771 | PMID 24248812 Get It

ABSTRACTGenes that alter disease risk only in combination with certain environmental exposures may not be detected in genetic association analysis. By using methods accounting for gene‐environment (G × E) interaction, we aimed to identify novel genetic loci associated with breast cancer risk. Up to 34,475 cases and 34,786 controls of European ancestry from up to 23 studies in the Breast Cancer Association Consortium were included. Overall, 71,527 single nucleotide polymorphisms (SNPs), enriched for association with breast cancer, were tested for interaction with 10 environmental risk factors using three recently proposed hybrid methods and a joint test of association and interaction. Analyses were adjusted for age, study, population stratification, and confounding factors as applicable. Three SNPs in two independent loci showed statistically significant association: SNPs rs10483028 and rs2242714 in perfect linkage disequilibrium on chromosome 21 and rs12197388 in ARID1B on chromosome 6. While rs12197388 was identified using the joint test with parity and with age at menarche (P‐values = 3 × 10−07), the variants on chromosome 21 q22.12, which showed interaction with adult body mass index (BMI) in 8,891 postmenopausal women, were identified by all methods applied. SNP rs10483028 was associated with breast cancer in women with a BMI below 25 kg/m2 (OR = 1.26, 95% CI 1.15–1.38) but not in women with a BMI of 30 kg/m2 or higher (OR = 0.89, 95% CI 0.72–1.11, P for interaction = 3.2 × 10−05). Our findings confirm comparable power of the recent methods for detecting G × E interaction and the utility of using G × E interaction analyses to identify new susceptibility loci.
A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46 450 cases and 42 461 controls from the breast cancer association consortium
Herránz, Jesús , Michailidou, Kyriaki , Zamora, M. Pilar , Pérez, José Ignacio Arias , González‐Neira, Anna , Pita, Guillermo , Alonso, M. Rosario, Wang, Qin , Bolla, Manjeet K. , Czene, Kamila , Eriksson, Mikael , Humphreys, Keith , Darabi, Hatef, Li, Jingmei , Hopper, John L. , Apicella, Carmel, Southey, Melissa C. , Chenevix‐Trench, Georgia , Investigators, kConFab, Group, Australian Ovarian Cancer Study, Swerdlow, Anthony J. , Ashworth, Alan , Orr, Nicholas, Schoemaker, Minouk J. , Jakubowska, Anna , Lubiński, Jan , Jaworska–Bieniek, Katarzyna, Durda, Katarzyna, Andrulis, Irene L. , Knight, Julia A. , Glendon, Gord, Mulligan, Anna Marie , Bojesen, Stig E. , Nordestgaard, Børge G. , Flyger, Henrik, Nevanlinna, Heli , Muranen, Taru , Aittomäki, Kristiina, Blomqvist, Carl , Chang‐Claude, Jenny , Flesch‐Janys, Dieter, Vachon, Celine M. , Purrington, Kristen S. , Winqvist, Robert , Pylkäs, Katri , Jukkola‐Vuorinen, Arja , Grip, Mervi, Dunning, Alison M. , Shah, Mitul , Guénel, Pascal , Truong, Thérèse , Sanchez, Marie, Mulot, Claire , Brenner, Hermann , Dieffenbach, Aida Karina, Stegmaier, Christa, Lindblom, Annika , Margolin, Sara , Hooning, Maartje J. , Hollestelle, Antoinette , Collée, J. Margriet, Jager, Agnes , Cox, Angela , Brock, Ian W., Reed, Malcolm , Devilee, Peter , Tollenaar, Robert A.E.M., Seynaeve, Caroline, Haiman, Christopher A., Henderson, Brian E., Schumacher, Fredrick R. , Simard, Jacques , Dumont, Martine , Soucy, Penny, Dörk, Thilo , Bogdanova, Natalia , Hamann, Ute , Rüdiger, Thomas , Ulmer, Hans-Ulrich, Fasching, Peter A. , Häberle, Lothar , Ekici, Arif B. , Beckmann, Matthias W. , Fletcher, Olivia , Johnson, Nichola , dos‐Santos‐Silva, Isabel , Peto, Julian, Radice, Paolo , Peterlongo, Paolo , Peissel, Bernard , Mariani, P., Severi, Gianluca , Baglietto, Laura , Sawyer, Elinor J. , Tomlinson, Ian , Kerin, Michael J. , Miller, Nicola, Marmé, F., Burwinkel, Barbara , Mannermaa, Arto, Kataja, Vesa , Kosma, Veli‐Matti , Hartikainen, Jaana M. , Lambrechts, Diether , Yesilyurt, Betül T., Floris, Giuseppe , Leunen, Karin, Alnæs, Grethe Grenaker, Kristensen, Vessela N. , Børresen‐Dale, Anne‐Lise , García‐Closas, Montserrat , Lissowska, Jolanta , Figueroa, Jonine D. , Schmidt, Marjanka K. , Verhoef, Senno, Rutgers, Emiel J. , Brauch, Hiltrud , Brüning, Thomas , Ko, Yon‐Dschun, Network, The GENICA, TNBCC, The, Yannoukakos, Drakoulis , Malats, Núria , Easton, Douglas F. , Manoukian, Siranoush , Durocher, Francine , Zaffaroni, Daniela , Orr, Nick , Thorne, Heather , Bowtell, David D.L. , Rabstein, Sylvia , Lotz, Anne , Lambrechts, Diether , Milne, Roger L. , Dennis, Joe , Tyrer, Jonathan P. , Eriksson, Mikael , Anton‐Culver, Hoda , Neuhausen, Susan L. , Ziogas, Argyrios , Clarke, Christina A. , Dite, Gillian S. , Investigators, kConFab, Group, Australian Ovarian Cancer Study, Orr, Nicholas, Rudolph, Anja , Seibold, Petra , Wang, Xianshu , Olson, Janet E. , Vachon, Celine M. , Sanchez, Marie, Arndt, Volker , Hooning, Maartje J. , Marchand, Loı̈c Le , Försti, Asta , Giles, Graham G. , Mannermaa, Arto, Chanock, Stephen Jacob , Broeks, Annegien , Network, The GENICA, Couch, Fergus J. , Toland, Amanda Ewart , TNBCC, The, Pharoah, Paul D.P. , Hall, Per N , Benı́tez, Javier , Nevanlinna, H , Dörk, Thilo , Lambrechts, Diether , Peterlongo, Paolo , Swerdlow, Anthony J , Radice, Paolo , Lissowska, Jolanta , Southey, Melissa C , Malats, Nuria , Dunning, Alison M , Jakubowska, Anna , Lambrechts, Diether , Brenner, Hermann , Cox, Angela , Guénel, Pascal , Li, Jingmei , Muranen, Taru A , García-Closas, Montserrat , Schmidt, Marjanka K , Severi, Gianluca , Ekici, Arif B , Michailidou, Kyriaki , Hartikainen, Jaana M , Bogdanova, Natalia V , Simard, Jacques , Chenevix-Trench, Georgia , Figueroa, Jonine D , Czene, Kamila , Bowtell, David D , Pylkäs, Katri , Yannoukakos, Drakoulis , Devilee, Peter , Manoukian, Siranoush , Lubinski, Jan , Baglietto, Laura , Fletcher, Olivia , Bojesen, Stig E , Purrington, Kristen S , Schoemaker, Minouk J , Truong, Therese , Brauch, Hiltrud , Lindblom, Annika , Sawyer, Elinor J , Orr, Nick

Mayo Clinic

Human Molecular Genetics | November 16, 2013 | Volume: 23 | Issue: 7 | Pages: 1934-1946

10.1093/hmg/ddt581 | PMID 24242184 Get It

Abstract Part of the substantial unexplained familial aggregation of breast cancer may be due to interactions between common variants, but few studies have had adequate statistical power to detect interactions of realistic magnitude. We aimed to assess all two-way interactions in breast cancer susceptibility between 70 917 single nucleotide polymorphisms (SNPs) selected primarily based on prior evidence of a marginal effect. Thirty-eight international studies contributed data for 46 450 breast cancer cases and 42 461 controls of European origin as part of a multi-consortium project (COGS). First, SNPs were preselected based on evidence (P < 0.01) of a per-allele main effect, and all two-way combinations of those were evaluated by a per-allele (1 d.f.) test for interaction using logistic regression. Second, all 2.5 billion possible two-SNP combinations were evaluated using Boolean operation-based screening and testing, and SNP pairs with the strongest evidence of interaction (P < 10−4) were selected for more careful assessment by logistic regression. Under the first approach, 3277 SNPs were preselected, but an evaluation of all possible two-SNP combinations (1 d.f.) identified no interactions at P < 10−8. Results from the second analytic approach were consistent with those from the first (P > 10−10). In summary, we observed little evidence of two-way SNP interactions in breast cancer susceptibility, despite the large number of SNPs with potential marginal effects considered and the very large sample size. This finding may have important implications for risk prediction, simplifying the modelling required. Further comprehensive, large-scale genome-wide interaction studies may identify novel interacting loci if the inherent logistic and computational challenges can be overcome.
Increased parental history of bipolar disorder in the United States: association with early age of onset
Post, Robert M. , Leverich, Gabriele S., Kupka, Ralph , Keck, P E, Altshuler, Lori L., Frye, Mark A. , Luckenbaugh, David A., Grunze, Heinz , Suppes, Trisha, Nolen, Willem A. , McElroy, Susan L. , Rowe, Michael J. , Grunze, Heinz

Mayo Clinic

Acta Psychiatrica Scandinavica | October 19, 2013 | Volume: 129 | Issue: 5 | Pages: 375-382

10.1111/acps.12208 | PMID 24138298 Get It

ObjectiveEarly‐onset bipolar (BP) disorder and other poor prognosis characteristics are more prevalent in patients from the United States than from the Netherlands and Germany (abbreviated as Europe). We explored the impact of parental loading for affective illness on onset and other characteristics of BP disorder.MethodParental history for unipolar (UP) and bipolar (BP) depression and course of illness characteristics were obtained from self‐report in adults (average age 42) with BP disorder. Illness characteristics were examined by χ2 and multinomial logistic regression in relationship to the degree of parental loading: i) both parents negative; ii) one UP disorder; iii) one with BP disorder; and iv) both affected.ResultsAfter controlling for many poor prognosis factors, compared with those from Europe, patients from the United States had more iii) one parent with BP disorder and iv) both parents affected. An early age of onset of BP disorder was independently associated with this increased parental loading for affective disorder.ConclusionParental history of BP disorder and both parents with a mood disorder were more common in the United States than Europe and were associated with an early onset of bipolar disorder and other poor prognosis characteristics. These findings deserve replication and exploration of the potential mechanisms involved and their therapeutic implications.
P1–229: sTNF‐R1 as a biomarker of Alzheimer's disease varies by APOE‐ε4 status
Edwards, Melissa, Como, Tori, Hall, James , Laske, Christoph , Graff‐Radford, Neill R. , Devous, Michael D. , Johnson, Leigh , Barber, Robert C. , O’Bryant, Sid E.

Mayo Clinic

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_6 | Pages: No page available

10.1016/j.jalz.2013.05.453 Get It

P1–225: IL7 and depression: The importance of gender and blood fraction
Hall, James , Edwards, Melissa, Como, Tori, Graff‐Radford, Neill R. , Devous, Michael D. , Johnson, Leigh , Barber, Robert C. , O’Bryant, Sid E.

Mayo Clinic

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_6 | Pages: No page available

10.1016/j.jalz.2013.05.449 Get It

P1–237: Thrombopoietin and Alzheimer's disease
Edwards, Melissa, Hall, James , Xiao, Guanghua , Rohlfing, Geoffrey, Devous, Michael D. , Graff‐Radford, Neill R. , Barber, Robert C. , Johnson, Leigh , O’Bryant, Sid E.

Mayo Clinic

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_6 | Pages: No page available

10.1016/j.jalz.2013.05.461 Get It

Comparison of Peripheral and Portal Venous Insulin Administration on Postprandial Metabolic Responses in Alloxan-Diabetic Dogs: Effects of Identical Preprogrammed Complex Insulin Infusion Waveforms
Rizza, R. A., Hall, Lea, Westland, R., Haymond, Morey W. , Clemens, A H, Gerich, John E., Service, F J, Fischer, Urs , Hall, Larry D., Service, F J

Mayo Clinic

Diabetes | September 19, 2013 | Volume: 31 | Issue: 7 | Pages: 579-584

10.2337/diab.31.7.579 | PMID 7160538 Get It

The optimal route for insulin administration by insulin infusion devices has not been established. To assess the differences between the peripheral venous and portal venous routes of insulin administration on postprandial metabolic responses, six alloxan-diabetic dogs were studied on four occasions. On the first, the insulin infusion rates given by the Biostator for disposal of a mixed meal were recorded electronically. On two subsequent occasions, these insulin infusion profiles were administered by a peripheral vein. On an additional occasion, the identical insulin infusion profile was given via the portal vein. No differences were observed in basal or peak plasma glucose, insulin, glucagon, branched chain amino acids, and lactate concentrations between portal and peripheral venous insulin administration. Furthermore, no differences in isotopically ([2-3H]glucose) determined rates of systemic glucose appearance and disappearance were observed between the two routes. Although preprandial plasma alanine concentrations were greater when insulin was infused via the portal vein, the postprandial increments did not differ from those observed during infusion of insulin by a peripheral vein. These studies suggest that under the current experimental conditions, there appears to be no difference in the disposition of a mixed meal, measured as net whole body glucose appearance and disappearance rates, when insulin is administered in an open-loop fashion via either a peripheral or the portal vein.
Lymphokine‐activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites
Jennings, V.A., Ilett, Elizabeth J. , Scott, Karen J. , Vile, Richard G. , Pandha, Hardev , Harrington, Kevin J. , Young, Alexandria N., Hall, G.D., Selby, Peter J. , Errington‐Mais, Fiona , Melcher, Alan , West, Emma J. , Coffey, Matt C. , Jennings, Victoria A. , Ilett, Elizabeth J , Errington-Mais, Fiona , Melcher, Alan A , Harrington, Kevin

Mayo Clinic

International Journal of Cancer | August 26, 2013 | Volume: 134 | Issue: 5 | Pages: 1091-1101

10.1002/ijc.28450 | PMID 23982804 Get It

Reovirus is an oncolytic virus (OV), which acts by both direct tumor cell killing and priming of antitumor immunity. A major obstacle for effective oncolytic virotherapy is effective delivery of OV to tumor cells. Ovarian cancer is often confined to the peritoneal cavity and therefore i.p. delivery of reovirus may provide the ideal locoregional delivery, avoiding systemic dissemination. However, ovarian cancer is associated with an accumulation of ascitic fluid, which may interfere with oncolytic viral therapy. Here, we investigated the effect of ascites on reovirus‐induced oncolysis against primary ovarian cancer cells and ovarian cancer cell lines. In the absence of ascites, reovirus was cytotoxic against ovarian cancer cells; however, cytotoxicity was abrogated in the presence of ascitic fluid. Neutralizing antibodies (NAb) were identified as the cause of this inhibition. Loading OV onto cell carriers may facilitate virus delivery in the presence of NAb and immune cells which have their own antitumor effector activity are particularly appealing. Immature dendritic cells (iDC), Lymphokine‐activated killer (LAK) cells and LAKDC cocultures were tested as potential carriers for reovirus for tumor cell killing and immune cell priming. Reovirus‐loaded LAKDC, and to a lesser degree iDC, were able to: (i) protect from NAb and hand‐off reovirus for tumor cell killing; (ii) induce a proinflammatory cytokine milieu (IFNɣ, IL‐12, IFNα and TNFα) and (iii) generate an innate and specific antitumor adaptive immune response. Hence, LAKDC pulsed with reovirus represent a novel, clinically practical treatment for ovarian cancer to maximise both direct and innate/adaptive immune‐mediated tumor cell killing.
CYP2B6*6 is associated with increased breast cancer risk
Justenhoven, Christina , Pentimalli, Daniela, Rabstein, Sylvia , Lotz, Anne , Pesch, Beate, Brüning, Thomas , Dörk, Thilo , Schürmann, Peter , Bogdanova, Natalia , Park‐Simon, Tjoung‐Won, Couch, Fergus J. , Fasching, Peter A. , Beckmann, Matthias W. , Häberle, Lothar , Ekici, Arif B. , Czene, Kamila , Liu, Janjun, Li, Jingmei , Baisch, Christian, Hamann, Ute , Ko, Yon‐Dschun, Brauch, Hiltrud , Harth, Volker , Park‐Simon, Tjoung‐Won , Couch, Fergus J. , Olson, Janet E. , Hall, Per N , Dörk, Thilo , Li, Jingmei , Ekici, Arif B , Bogdanova, Natalia V , Czene, Kamila , Brauch, Hiltrud

Mayo Clinic

International Journal of Cancer | July 3, 2013 | Volume: 134 | Issue: 2 | Pages: 426-430

10.1002/ijc.28356 | PMID 23824676 Get It

The cytochrome P450 2B6 (CYP2B6) is involved in the metabolism of testosterone. Functional changes in this enzyme may influence endogenous hormone exposure, which has been associated with risk of breast cancer. To assess potential associations between two functional polymorphisms CYP2B6_516_G>T (rs3745274) and CYP2B6_785_A>G (rs2279343) and breast cancer risk, we established a specific matrix‐assisted laser desorption/ionization time‐of‐flight mass spectrometry assay. The GENICA breast cancer case–control study showed associations between the variant genotypes CYP2B6_516_TT and CYP2B6_785_GG and breast cancer risk with odds ratios (ORs) of 1.34 (p = 0.001) and 1.31 (p = 0.002), respectively. A similar effect was observed for carriers of the CYP2B6_516_T allele in a validation study including four independent studies from Germany, Sweden and USA. In a pooled analysis of all five studies involving 4,638 breast cancer cases and 3,594 controls of European ancestry, carriers of the CYP2B6_516_G and the CYP2B6_785_G variant had an increased breast cancer risk with ORs of 1.10 (p = 0.027) and 1.10 (p = 0.031), respectively. We conclude that the genetic variants CYP2B6_516_G and CYP2B6_785_G (designated CYP2B6*6), which are known to decrease activity of the CYP2B6 enzyme, contribute to an increased breast cancer risk.